About Prothena
Prothena is a company based in Dublin (Ireland) founded in 2012.. The company has 163 employees as of December 31, 2024. Prothena offers products and services including Birtamimab, Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), and PRX012. Prothena operates in a competitive market with competitors including Jazz Pharmaceuticals, Neurocrine, PTC Therapeutics, Biohaven Pharmaceutical and Sana Biotechnology, among others.
- Headquarter Dublin, Ireland
- Employees 163 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Prothena Corporation Plc
-
Annual Revenue
$135.16 M47.92as on Dec 31, 2024
-
Net Profit
$-122.31 M16.81as on Dec 31, 2024
-
EBITDA
$-150.98 M17.33as on Dec 31, 2024
-
Latest Funding Round
$50 M (USD), Post-IPO
Mar 21, 2018
-
Investors
-
Employee Count
163
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Prothena
Prothena is a publicly listed company on the NASDAQ with ticker symbol PRTA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Prothena
Prothena offers a comprehensive portfolio of products and services, including Birtamimab, Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), and PRX012. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigational drug for AL Amyloidosis treatment in trials.
Drug candidate for Parkinson’s Disease management.
Targets ATTR Amyloidosis in clinical development.
Investigational option for specific amyloid-related conditions.
Candidate for Alzheimer’s Disease therapeutic applications.
Unlock access to complete
Unlock access to complete
Leadership Team
28 people
Finance and Accounting
7 people
Software Development Team
5 people
Human Resources and Administration
4 people
Legal and Compliance
3 people
Sales and Marketing
2 people
Scientist Team
2 people
Senior Team
2 people
Unlock access to complete
Funding Insights of Prothena
- Total Funding Total Funding
- Total Rounds 1
- Last Round Post-IPO — $50.0M
-
First Round
First Round
(21 Mar 2018)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2018 | Amount | Post-IPO - Prothena | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Prothena
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Prothena
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Prothena Comparisons
Competitors of Prothena
Prothena operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Neurocrine, PTC Therapeutics, Biohaven Pharmaceutical and Sana Biotechnology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Therapies for psychosis and cognitive impairment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Prothena
Frequently Asked Questions about Prothena
When was Prothena founded?
Prothena was founded in 2012 and raised its 1st funding round 6 years after it was founded.
Where is Prothena located?
Prothena is headquartered in Dublin, Ireland.
How many employees does Prothena have?
As of Dec 31, 2024, the latest employee count at Prothena is 163.
What is the annual revenue of Prothena?
Annual revenue of Prothena is $135.16M as on Dec 31, 2024.
What does Prothena do?
Prothena was founded in 2012 and is headquartered in Dublin, Ireland. Antibody-based therapies are developed by the company for conditions including AL amyloidosis, Parkinsons disease, and psoriasis. Operations are conducted within the biotechnology sector, where research and clinical development focus on protein misfolding disorders and autoimmune diseases. Services encompass drug discovery and therapeutic advancement, with activities spanning preclinical to clinical stages across international collaborations.
Who are the top competitors of Prothena?
Prothena's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
What products or services does Prothena offer?
Prothena offers Birtamimab, Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), and PRX012.
Is Prothena publicly traded?
Yes, Prothena is publicly traded on NASDAQ under the ticker symbol PRTA.
What is Prothena's ticker symbol?
The ticker symbol of Prothena is PRTA on NASDAQ.